Photo by argueta314 from unsplash
An unmet need exists for effective glucocorticoid-sparing agents for the treatment of giant cell arteritis (GCA). Tocilizumab, the first intervention to demonstrate substantial therapeutic benefits for patients with newly diagnosed… Click to show full abstract
An unmet need exists for effective glucocorticoid-sparing agents for the treatment of giant cell arteritis (GCA). Tocilizumab, the first intervention to demonstrate substantial therapeutic benefits for patients with newly diagnosed or relapsing GCA, is changing the landscape of treatment and ushering in a new era of biologic therapy.
Keywords:
frontier gca;
syndromes tocilizumab;
vasculitis syndromes;
tocilizumab new;
new frontier;
therapy
Journal Title: Nature Reviews Rheumatology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Nature Reviews Rheumatology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!